Miller JJ, Wen PY

Emerging targeted therapies for glioma.

Expert Opin Emerg Drugs 21:441-452 (2016)
DOI:10.1080/14728214.2016.1257609

Szerlip NJ, Pedraza A, Chakravarty D, Azim M, McGuire J, Fang Y, Ozawa T, Holland EC, Huse JT, Jhanwar S, Leversha MA, Mikkelsen T, Brennan CW

Intratumoral heterogeneity of receptor tyrosine kinases EGFR and PDGFRA amplification in glioblastoma defines subpopulations with distinct growth factor response.

Proc Natl Acad Sci U S A 109:3041-6 (2012)
DOI:10.1073/pnas.1114033109

Sugano K, Kakizoe T.

Genetic alterations in bladder cancer and their clinical applications in molecular tumor staging.

Nat Clin Pract Urol 3:642-52 (2006)
DOI:10.1038/ncpuro0649

Wolff EM, Liang G, Jones PA.

Mechanisms of Disease: genetic and epigenetic alterations that drive bladder cancer.

Nat Clin Pract Urol 2:502-10 (2005)
DOI:10.1038/ncpuro0318

Toyooka S, Mitsudomi T, Soh J, Aokage K, Yamane M, Oto T, Kiura K, Miyoshi S

Molecular oncology of lung cancer.

Gen Thorac Cardiovasc Surg 59:527-37 (2011)
DOI:10.1007/s11748-010-0743-3

Lee DH

Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures.

Pharmacol Ther 174:1-21 (2017)
DOI:10.1016/j.pharmthera.2017.02.001

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

N Engl J Med 350:2129-39 (2004)
DOI:10.1056/NEJMoa040938

Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR, Meyerson M

Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants.

PLoS Med 2:e313 (2005)
DOI:10.1371/journal.pmed.0020313

Yasuda H, Kobayashi S, Costa DB

EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications.

Lancet Oncol 13:e23-31 (2012)
DOI:10.1016/S1470-2045(11)70129-2

Sullivan I, Planchard D

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line.

Front Med (Lausanne) 3:76 (2016)
DOI:10.3389/fmed.2016.00076

Fleming TP, Saxena A, Clark WC, Robertson JT, Oldfield EH, Aaronson SA, Ali IU

Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors.

Cancer Res 52:4550-3 (1992)

Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H, Bando M, Ohno S, Ishikawa Y, Aburatani H, Niki T, Sohara Y, Sugiyama Y, Mano H

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Nature 448:561-6 (2007)
DOI:10.1038/nature05945

Bayliss R, Choi J, Fennell DA, Fry AM, Richards MW

Molecular mechanisms that underpin EML4-ALK driven cancers and their response to targeted drugs.

Cell Mol Life Sci 73:1209-24 (2016)
DOI:10.1007/s00018-015-2117-6

Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Janne PA

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.

Cancer Res 70:10038-43 (2010)
DOI:10.1158/0008-5472.CAN-10-2956